标题
The therapeutic potential of targeting tryptophan catabolism in cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 122, Issue 1, Pages 30-44
出版商
Springer Science and Business Media LLC
发表日期
2019-12-10
DOI
10.1038/s41416-019-0664-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
- (2019) Geoffrey T. Gibney et al. Journal for ImmunoTherapy of Cancer
- Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
- (2019) Michael Platten et al. NATURE REVIEWS DRUG DISCOVERY
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- A novel dual inhibitor of IDO and TDO, CMG017, potently suppresses the kynurenine pathway and overcomes resistance to immune checkpoint inhibitors.
- (2019) Chan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
- (2019) Maisa C. Takenaka et al. NATURE NEUROSCIENCE
- IDO1 maintains pluripotency of primed human embryonic stem cells by promoting glycolysis
- (2019) Xin Liu et al. STEM CELLS
- Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis
- (2019) Wei-Min Chung et al. Cancers
- Serine-Glycine-One-Carbon Metabolism: The Hidden Achilles Heel of MYCN-Amplified Neuroblastoma?
- (2019) Aida Rodriguez Garcia et al. CANCER RESEARCH
- Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas
- (2019) Shuyu Hao et al. JOURNAL OF NEURO-ONCOLOGY
- Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice
- (2019) Timothy Affolter et al. PLoS One
- Kynurenine signaling through the aryl hydrocarbon receptor maintains the undifferentiated state of human embryonic stem cells
- (2019) Takako Yamamoto et al. Science Signaling
- Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells
- (2019) Naoya Yamashita et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer
- (2019) Niranjan Venkateswaran et al. GENES & DEVELOPMENT
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis
- (2019) Richard H. Kimura et al. Nature Communications
- Development of a mass spectrometry-based tryptophan 2, 3-dioxygenase assay using liver cytosol from multiple species
- (2018) Jing Wang et al. ANALYTICAL BIOCHEMISTRY
- Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma
- (2018) E Tina et al. BRITISH JOURNAL OF DERMATOLOGY
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation
- (2018) Yuying Liu et al. CANCER CELL
- A patent review of IDO1 inhibitors for cancer
- (2018) Jae Eun Cheong et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- HOXC10 promotes proliferation and invasion and induces immunosuppressive gene expression in glioma
- (2018) Shu Li et al. FEBS Journal
- Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
- (2018) Cristina Gutiérrez-Vázquez et al. IMMUNITY
- Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
- (2018) Todd A Triplett et al. NATURE BIOTECHNOLOGY
- The T-win® technology: immune-modulating vaccines
- (2018) Mads Hald Andersen Seminars in Immunopathology
- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
- (2018) Asha Nayak-Kapoor et al. Journal for ImmunoTherapy of Cancer
- Human AML activates the AHR pathway to impair NK cell development and function
- (2018) Steven D. Scoville et al. BLOOD
- The roles of the COX2/PGE2/EP axis in therapeutic resistance
- (2018) Dali Tong et al. CANCER AND METASTASIS REVIEWS
- Expression of the IDO1/TDO2–AhR pathway in tumor cells or the tumor microenvironment is associated with MCPyV status and prognosis in Merkel cell carcinoma
- (2018) Lusi Oka Wardhani et al. HUMAN PATHOLOGY
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
- (2018) Timothy Anthony Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- A Role for Tryptophan-2,3-dioxygenase in CD8 T Cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
- (2018) Lisa I Greene et al. MOLECULAR CANCER RESEARCH
- Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
- (2018) Bruno Gomes et al. MOLECULAR CANCER THERAPEUTICS
- TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma
- (2018) Quoc Thang Pham et al. ONCOLOGY
- Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML)
- (2018) Melanie Gentil et al. PLoS One
- Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
- (2018) Julie Westerlin Kjeldsen et al. Frontiers in Immunology
- Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
- (2018) Eric Fox et al. Frontiers in Oncology
- Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases
- (2018) Linnéa Schmidt et al. BRITISH JOURNAL OF CANCER
- Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase
- (2018) Maria Winters et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Current state on tryptophan 2,3-dioxygenase inhibitors: a patent review
- (2018) Arina Kozlova et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Invasion and migration of MDA-MB-231 cells are inhibited by block of AhR and NFAT: role of AhR/NFAT1/β4 integrin signaling
- (2018) Amir Shadboorestan et al. JOURNAL OF APPLIED TOXICOLOGY
- Cyclooxygenase-2 in cancer: A review
- (2018) Nasser Hashemi Goradel et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma
- (2018) Sébastien Corre et al. Nature Communications
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- Epigenetic Strategies to Boost Cancer Immunotherapies
- (2017) Maria Barrero INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
- (2017) Stefano Crosignani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chromatographic analysis of tryptophan metabolites
- (2017) Ilona Sadok et al. JOURNAL OF SEPARATION SCIENCE
- Pre-Interventional Kynurenine Predicts Medium-Term Outcome after Contrast Media Exposure Due to Coronary Angiography
- (2017) Christoph Reichetzeder et al. KIDNEY & BLOOD PRESSURE RESEARCH
- ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS
- (2017) David Reardon et al. NEURO-ONCOLOGY
- Preparation and evaluation of L- and D-5-[ 18 F]fluorotryptophan as PET imaging probes for indoleamine and tryptophan 2,3-dioxygenases
- (2017) Tang Tang et al. NUCLEAR MEDICINE AND BIOLOGY
- Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
- (2017) Benjamin J. Moyer et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Synthesis of 5-[18F]Fluoro-α-methyl Tryptophan: New Trp Based PET Agents
- (2017) Benjamin C. Giglio et al. Theranostics
- Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer
- (2017) Sewha Kim et al. Journal of Cancer
- Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
- (2017) Marc Hennequart et al. Cancer Immunology Research
- Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer
- (2017) Dyah L. Dewi et al. OncoImmunology
- Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
- (2017) Pilvi Maliniemi et al. OncoImmunology
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
- (2017) Daniel E. Carvajal-Hausdorf et al. Journal for ImmunoTherapy of Cancer
- Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice
- (2016) Paul B. Larkin et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- 1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)
- (2016) Ute F. Röhrig et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients
- (2016) Jayakumar Hascitha et al. CLINICAL BIOCHEMISTRY
- Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
- (2016) A. M. Monjazeb et al. CLINICAL CANCER RESEARCH
- The end of the road for the tryptophan depletion concept in pregnancy and infection
- (2016) A. A.- B. Badawy et al. CLINICAL SCIENCE
- Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
- (2016) Jon Bjoern et al. CYTOTHERAPY
- Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma
- (2016) Ahlem Ben-Haj-Ayed et al. IMMUNOLOGY LETTERS
- Tolerogenic Phenotype of IFN-γ–Induced IDO+Dendritic Cells Is Maintained via an Autocrine IDO–Kynurenine/AhR–IDO Loop
- (2016) Qingsheng Li et al. JOURNAL OF IMMUNOLOGY
- Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4
- (2016) Katharina Ochs et al. JOURNAL OF NEUROCHEMISTRY
- General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation
- (2016) Melanie Keil et al. JOURNAL OF NEUROIMMUNOLOGY
- Assessment of Tryptophan Uptake and Kinetics Using 1-(2- 18 F-Fluoroethyl)-l-Tryptophan and α- 11 C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts
- (2016) Sharon K. Michelhaugh et al. JOURNAL OF NUCLEAR MEDICINE
- Improved Radiosynthesis and Biological Evaluations of L- and D-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of IDO-Mediated Kynurenine Pathway of Tryptophan Metabolism
- (2016) Yangchun Xin et al. MOLECULAR IMAGING AND BIOLOGY
- Fully automated radiosynthesis of N1-[18F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging
- (2016) Jean Henrottin et al. NUCLEAR MEDICINE AND BIOLOGY
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment
- (2016) Cara C. Schafer et al. Oncotarget
- Stress Kinase GCN2 Controls the Proliferative Fitness and Trafficking of Cytotoxic T Cells Independent of Environmental Amino Acid Sensing
- (2016) Lee-Ann Van de Velde et al. Cell Reports
- The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas
- (2016) Jana K. Sonner et al. OncoImmunology
- Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma
- (2016) Anthony R. Guastella et al. Molecular Imaging
- IDO1 is an Integral Mediator of Inflammatory Neovascularization
- (2016) Arpita Mondal et al. EBioMedicine
- The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis
- (2016) Yuhei Shibata et al. PLoS One
- A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
- (2015) Nicholas C. D'Amato et al. CANCER RESEARCH
- Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice
- (2015) Manabu Takamatsu et al. CANCER SCIENCE
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity
- (2015) Buvana Ravishankar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The breakdown of the anelastic approximation in rotating compressible convection: implications for astrophysical systems
- (2015) M. A. Calkins et al. PROCEEDINGS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES
- NAD+ in aging, metabolism, and neurodegeneration
- (2015) E. Verdin SCIENCE
- Differential Regulation of Th17 and T Regulatory Cell Differentiation by Aryl Hydrocarbon Receptor Dependent Xenobiotic Response Element Dependent and Independent Pathways
- (2015) Sonia Mohinta et al. TOXICOLOGICAL SCIENCES
- N1-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase
- (2015) Jean Henrottin et al. ACS Medicinal Chemistry Letters
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan
- (2015) N. van Baren et al. Cancer Immunology Research
- Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer
- (2015) Mads Duus Hjortsø et al. OncoImmunology
- Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
- (2015) Nathalie Vigneron et al. OncoImmunology
- Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
- (2015) Tara C Gangadhar et al. Journal for ImmunoTherapy of Cancer
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
- (2015) Ulrike M. Litzenburger et al. Oncotarget
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- The Aryl Hydrocarbon Receptor: Multitasking in the Immune System
- (2014) Brigitta Stockinger et al. Annual Review of Immunology
- Inhibition of De Novo NAD + Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage
- (2014) Krishna S. Tummala et al. CANCER CELL
- Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway
- (2014) Martina Ott et al. GLIA
- IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation
- (2014) Richard Metz et al. INTERNATIONAL IMMUNOLOGY
- The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells
- (2014) S. Trabanelli et al. JOURNAL OF IMMUNOLOGY
- Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives IL-22 Production
- (2014) Margaret M. Lowe et al. PLoS One
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- IDO2 in Immunomodulation and Autoimmune Disease
- (2014) George C. Prendergast et al. Frontiers in Immunology
- The Role of Placental Tryptophan Catabolism
- (2014) Peter Sedlmayr et al. Frontiers in Immunology
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice
- (2013) Heloisa Orsini et al. BRAIN BEHAVIOR AND IMMUNITY
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation
- (2013) Christoph F A Vogel et al. IMMUNOLOGY AND CELL BIOLOGY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
- (2013) J. Yu et al. JOURNAL OF IMMUNOLOGY
- Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration
- (2013) Xiao-Qian Liu et al. LEUKEMIA & LYMPHOMA
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- The Genotype-Tissue Expression (GTEx) project
- (2013) John Lonsdale et al. NATURE GENETICS
- Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain
- (2013) Wei Wu et al. PLoS One
- Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
- (2013) Ben C. Creelan et al. OncoImmunology
- Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase
- (2012) Mee Young Chang et al. CANCER BIOLOGY & THERAPY
- Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation
- (2012) Feng Qian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation
- (2012) Vera Levina et al. Clinical & Developmental Immunology
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
- (2012) Courtney Smith et al. Cancer Discovery
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
- (2011) R. B. Sorensen et al. CANCER RESEARCH
- Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
- (2011) Jonathan R. Brody et al. CELL CYCLE
- High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma
- (2011) Jocelyne Jacquemier et al. INTERNATIONAL JOURNAL OF CANCER
- Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
- (2011) Eduard Dolušić et al. JOURNAL OF MEDICINAL CHEMISTRY
- Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase
- (2011) R Meisel et al. LEUKEMIA
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
- (2010) R. B. Sorensen et al. BLOOD
- The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth
- (2010) C. Dietrich et al. CARCINOGENESIS
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
- (2010) N. T. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis
- (2010) F. J. Quintana et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
- (2010) Anthony E. Boitano et al. SCIENCE
- CH223191 Is a Ligand-Selective Antagonist of the Ah (Dioxin) Receptor
- (2010) Bin Zhao et al. TOXICOLOGICAL SCIENCES
- Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
- (2010) Brett C. DiNatale et al. TOXICOLOGICAL SCIENCES
- Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
- (2009) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells
- (2009) M. Brenk et al. JOURNAL OF IMMUNOLOGY
- Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
- (2009) Agnieszka K. Witkiewicz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
- (2009) Rikke Bæk Sørensen et al. PLoS One
- Infectious tolerance via the consumption of essential amino acids and mTOR signaling
- (2009) S. P. Cobbold et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-β and Protein Kinase R
- (2009) Christiane A. Opitz et al. STEM CELLS
- Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1)
- (2009) Tobias V. Lanz et al. STEM CELLS AND DEVELOPMENT
- Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice
- (2009) Masaaki Kanai et al. Molecular Brain
- Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
- (2008) Christoph F.A. Vogel et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
- (2008) Stefan Löb et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
- (2008) K. Ino et al. CLINICAL CANCER RESEARCH
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
- (2008) Ke Pan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection
- (2008) Agnes Witkiewicz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Immune escape as a fundamental trait of cancer: focus on IDO
- (2008) G C Prendergast ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started